Interferon-?-Inducible Chemokines as Prognostic Markers for Lung Cancer

Keu-Sung Lee, Wou-Young Chung, Ji-Eun Park, Yun-Jung Jung, Joo-Hun Park, Seung-Soo Sheen and Kwang-Joo Park
Additional contact information
Keu-Sung Lee: Department of Pulmonology and Critical Care Medicine, Ajou University School of Medicine, Suwon 16499, Korea
Wou-Young Chung: Department of Pulmonology and Critical Care Medicine, Ajou University School of Medicine, Suwon 16499, Korea
Ji-Eun Park: Department of Pulmonology and Critical Care Medicine, Ajou University School of Medicine, Suwon 16499, Korea
Yun-Jung Jung: Department of Pulmonology and Critical Care Medicine, Ajou University School of Medicine, Suwon 16499, Korea
Joo-Hun Park: Department of Pulmonology and Critical Care Medicine, Ajou University School of Medicine, Suwon 16499, Korea
Seung-Soo Sheen: Department of Pulmonology and Critical Care Medicine, Ajou University School of Medicine, Suwon 16499, Korea
Kwang-Joo Park: Department of Pulmonology and Critical Care Medicine, Ajou University School of Medicine, Suwon 16499, Korea

IJERPH, 2021, vol. 18, issue 17, 1-10

Abstract: Interferon (IFN)-?-inducible chemokines in the CXCR3/ligand axis are involved in cell-mediated immunity and play a significant role in the progression of cancer. We enrolled patients with lung cancer ( n = 144) and healthy volunteers as the controls ( n = 140). Initial blood samples were collected and concentrations of IFN-? and IFN-?-inducible chemokines CXCL9, CXCL10, and CXCL11 were measured using enzyme-linked immunosorbent assay. Of patients with lung cancer, 125 had non-small cell lung cancer (NSCLC) and 19 had small cell lung cancer. The area under the curve (AUC) (95% CI) of CXCL9 was 0.83 (0.80–0.89) for differentiating lung cancer patients from controls. The levels of all the markers were significantly higher in NSCLC patients with stage IV than in those with stages I–III. A Kaplan-Meier survival analysis showed that NSCLC cancer patients with higher levels of all markers showed poorer survival than those with lower levels. In Cox multivariate analysis of patients with NSCLC, independent prognostic factors for overall survival were CXCL9 and CXCL11. CXCL9 was the only independent prognostic factor for cancer-specific survival. Serum IFN-?-inducible chemokines may be useful as clinical markers of metastasis and prognosis in NSCLC, and CXCL9 levels showed the most significant results.

Keywords: cell-mediated immunity; lung cancer; interferon-?; CXCR3 ligand; biomarker; prognosis (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/17/9345/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/17/9345/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:17:p:9345-:d:628964

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().